United Therapeutics Corporation (UTHR) Stock Forecast
UTHR analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.13 / 5 from 15 analysts
- Price target
- $656.93 average of analyst targets
- Upside to target
- +23.2% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $6.25
- 52-week range
- $415.34 – $596.76
UTHR analyst ratings
15 analystsNumber of analysts at each rating.
UTHR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
UTHR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $6.21 | $4.40 | $7.26 | $7.16 | −13.2% | 13 |
| Current fiscal year (2026) | $26.45 | $22.65 | $28.68 | $27.86 | −5.1% | 13 |
| Next fiscal year (2027) | $31.21 | $21.87 | $45.11 | $26.45 | +18.0% | 13 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
UTHR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $784.2M | $751.0M | $807.0M | −1.9% | 12 |
| Current fiscal year (2026) | $3.19B | $3.05B | $3.44B | +0.2% | 13 |
| Next fiscal year (2027) | $3.61B | $2.80B | $4.22B | +13.3% | 13 |
UTHR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
UTHR revenue: reported and forecast
UTHR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $7.00 | $6.45 | $6.44 | $6.21 | $6.21 | −11.3% | 1 up · 2 down |
| Current fiscal year (2026) | $26.85 | $26.27 | $26.04 | $26.16 | $26.45 | −1.5% | 3 up · 1 down |
| Next fiscal year (2027) | $31.49 | $28.94 | $28.69 | $30.20 | $31.21 | −0.9% | 4 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
UTHR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; UTHR beat in 7 of 12.
What analysts expect from UTHR
15 analysts cover United Therapeutics; their consensus rating is buy (4.13 on a 1–5 scale, where 5 is a strong buy). The average price target is $656.93, 23.2% above the latest close of $533.12. Analysts expect earnings of $26.45 per share for 2026, −5.1% from a year earlier. For 2027 the average estimate is $31.21 per share on revenue of $3.6 billion. United Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: UTHR income statement, UTHR key metrics, UTHR chart. See the UTHR stock overview for the latest quote and news.
UTHR forecast FAQ
What is United Therapeutics's price target?
The average analyst price target for United Therapeutics is $656.93, 23.2% above the latest close of $533.12.
Is United Therapeutics a buy, hold or sell?
Of 15 analysts covering United Therapeutics, 8 rate it a strong buy, 3 a buy, 3 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is United Therapeutics's EPS forecast?
Analysts forecast $26.45 per share for 2026 (range $22.65 to $28.68); for 2027 the estimate is $31.21.
What is United Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $3.2 billion, growth of 0.2%; for 2027 it is $3.6 billion.
When does United Therapeutics report earnings?
United Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $6.25.
Does United Therapeutics usually beat earnings estimates?
United Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.